Stock Events

Stock Events

Oryzon Genomics. 

€2.73
79
+€0.1+3.61% Today

Statistics

Day High
2.63
Day Low
2.63
52W High
3.98
52W Low
2.5
Volume
-
Avg. Volume
-
Mkt Cap
214.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.05
-0.03
-0.02
-0
Expected EPS
-0.04907038232
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.33MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORN.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Protagonist Therapeutics
PTGX
Mkt Cap4.89B
Protagonist Therapeutics, Inc. is involved in the discovery and development of innovative peptide-based drugs, overlapping with Oryzon's therapeutic areas.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG specializes in gene editing, a cutting-edge area of biotechnology that could compete with Oryzon's genomic approaches.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. works on genomic therapies, including gene editing and gene regulation, directly competing with Oryzon's genomic focus.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its extensive research in oncology and gene therapy, competes across multiple fronts with Oryzon's therapeutic developments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is a major player in the development of innovative therapies, including oncology and inflammatory diseases, areas that Oryzon is also targeting.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. has a broad portfolio in biotechnology treatments, including oncology and hematology, competing with Oryzon's research and development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals Incorporated is known for its work in treating genetic diseases, potentially competing with Oryzon's genomic and epigenetic approaches.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. specializes in enzyme replacement therapies and rare genetic diseases treatment, overlapping with Oryzon's focus on innovative and targeted therapies.

About

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Show more...
CEO
Dr. Carlos Manuel Buesa Arjol
Employees
47
Country
ES
ISIN
ES0167733015
WKN
000A2ACV2

Listings

LSE
GB
0RDB.LSE
F
DE
ORN.F
OTC Link
US
ORYZF
MC
ES
ORY.MC

0 Comments

Share your thoughts

FAQ

What is Oryzon Genomics. stock price today?▼
The current price of ORN.F is €2.73 EUR — it has increased by +3.61% in the past 24 hours. Watch Oryzon Genomics. stock price performance more closely on the chart.
What is Oryzon Genomics. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oryzon Genomics. stocks are traded under the ticker ORN.F.
Is Oryzon Genomics. stock price growing?▼
ORN.F stock has risen by +0.93% compared to the previous week, the month change is a -13.49% fall, over the last year Oryzon Genomics. has showed a -13.35% decrease.
What is Oryzon Genomics. market cap?▼
Today Oryzon Genomics. has the market capitalization of 214.04M
When is the next Oryzon Genomics. earnings date?▼
Oryzon Genomics. is going to release the next earnings report on May 18, 2026.
What were Oryzon Genomics. earnings last quarter?▼
ORN.F earnings for the last quarter are -0.02 EUR per share, whereas the estimation was -0.03 EUR resulting in a +41.88% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Oryzon Genomics. revenue for the last year?▼
Oryzon Genomics. revenue for the last year amounts to 0 EUR.
What is Oryzon Genomics. net income for the last year?▼
ORN.F net income for the last year is -7.33M EUR.
How many employees does Oryzon Genomics. have?▼
As of April 01, 2026, the company has 47 employees.
In which sector is Oryzon Genomics. located?▼
Oryzon Genomics. operates in the Health Care sector.
When did Oryzon Genomics. complete a stock split?▼
Oryzon Genomics. has not had any recent stock splits.
Where is Oryzon Genomics. headquartered?▼
Oryzon Genomics. is headquartered in Cornellà de Llobregat, ES.